Eli Lilly filed a NAFTA arbitration claim against Canada seeking $500 million in compensation. Lilly alleges that Canadian courts violated NAFTA and other international agreements by invalidating patents on Lilly's Strattera and Zyprexa drugs. Specifically, Lilly argues the courts used new legal standards around demonstrating usefulness that were not previously applied and discriminate against pharmaceutical patents. The arbitration is expected to take two years to resolve before a three-person panel. The case follows a recent decision dismissing a similar claim by a Canadian generic drug company against the United States.